{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T13:19:05Z","timestamp":1761311945700,"version":"3.37.3"},"reference-count":8,"publisher":"Japan Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1507\/endocrj.ej22-0560","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T22:17:36Z","timestamp":1674598656000},"page":"229-232","source":"Crossref","is-referenced-by-count":3,"title":["Complete and sustained remission of hypercortisolism with pasireotide treatment of an adrenocorticotropic hormone (ACTH)-secreting thoracic neuroendocrine tumor: an n-of-1 trial"],"prefix":"10.1507","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7345-7912","authenticated-orcid":false,"given":"Zoe A.","family":"Efstathiadou","sequence":"first","affiliation":[{"name":"Department of Endocrinology, \u201cHippokration\u201d General Hospital of Thessaloniki, Thessaloniki 54642, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efstathios","family":"Divaris","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, \u201cHippokration\u201d General Hospital of Thessaloniki, Thessaloniki 54642, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasia","family":"Michou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, \u201cHippokration\u201d General Hospital of Thessaloniki, Thessaloniki 54642, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Kyriakopoulos","sequence":"additional","affiliation":[{"name":"Department of Pathology, \u201cEvaggelismos\u201d General Hospital of Athens, Athens 10676, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina D.","family":"Kita","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, \u201cHippokration\u201d General Hospital of Thessaloniki, Thessaloniki 54642, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, et al. (2017) Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 18: 1652\u20131664.","DOI":"10.1016\/S1470-2045(17)30681-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, et al. (2014) Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing\u2019s disease: results from a Phase III study. Clin Endocrinol (Oxf) 81: 408\u2013417.","DOI":"10.1111\/cen.12431"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Srirajaskanthan R, Watkins J, Marelli L, Khan K, Caplin ME (2009) Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies. Neuroendocrinology 89: 308\u2013314.","DOI":"10.1159\/000179899"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Vitale G, Dicitore A, Sciammarella C, Di Molfetta S, Rubino M, et al. (2018) Pasireotide in the treatment of neuroendocrine tumors: a review of the literature. Endocr Relat Cancer 25: R351\u2013R364.","DOI":"10.1530\/ERC-18-0010"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Kvols LK, Oberg KE, O\u2019Dorisio TM, Mohideen P, de Herder WW, et al. (2012) Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer 19: 657\u2013666.","DOI":"10.1530\/ERC-11-0367"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Mohamed A, Blanchard MP, Albertelli M, Barbieri F, Brue T, et al. (2014) Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. Endocr Relat Cancer 21: 691\u2013704.","DOI":"10.1530\/ERC-14-0086"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Golor G, Hu K, Ruffin M, Buchelt A, Bouillaud E, et al. (2012) A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther 6: 71\u201379.","DOI":"10.2147\/DDDT.S29125"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Nedelman J, Fisch R, Hu K, Paule I, Zhou J (2018) Population pharmacokinetics of subcutaneous pasireotide in healthy volunteers and Cushing\u2019s disease patients. Clin Pharmacokinet 57: 855\u2013866.","DOI":"10.1007\/s40262-017-0600-y"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/70\/2\/70_EJ22-0560\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T03:17:15Z","timestamp":1677899835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/70\/2\/70_EJ22-0560\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej22-0560","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"type":"print","value":"0918-8959"},{"type":"electronic","value":"1348-4540"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"EJ22-0560"}}